Drug intelligence / Profile preview

AAV-GAD67 gene therapy

Development stage
Unknown
Lead developer
MeiraGTx Holdings
Modality
Gene Therapies
Administration
Intraparenchymal, Intraperitoneal
01

Overview

AAV-GAD67 gene therapy is a therapeutic approach using adeno-associated virus (AAV) vectors to deliver the GAD1 gene, which encodes the 67 kDa isoform of glutamic acid decarboxylase (GAD67). GAD67 is a key enzyme that catalyzes the conversion of the excitatory neurotransmitter glutamate into the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). This modality is designed to restore the balance between neuronal excitation and inhibition in neurological disorders. In Parkinson's disease, it has been developed as part of a dual-vector system (AAV-GAD or NLX-P101) to modulate the subthalamic nucleus. In epilepsy research, it is being explored as a method to enhance tonic inhibition and suppress seizures in drug-resistant patients.

Other names
AAV-GAD67AAV-GAD-67AAV-GAD 67AAV-GAD1 gene therapyAAV-GAD-1 gene therapyAAV-GAD 1 gene therapy
02

Targets

HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))GAD1 (Glutamate decarboxylase 1)

Beyond the preview

Go deeper on AAV-GAD67 gene therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV-GAD67 gene therapy.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call